Johnson & Johnson’s gene therapy for X-linked retinal pigmentosa did not meet the main vision goal of a pivotal study. J&J secured full rights to the program from gene therapy biotech MeiraGtx in 2023.
The post J&J Gene Therapy for Rare, Progressive Vision-Loss Disorder Fails Phase 3 Test appeared first on MedCity News.
